Disclosures

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 24 months from the start of or during the production of the work and that are relevant to the author’s content. If an author has such a financial interest, then s/he must disclose the name of the commercial interest and nature of the relationship (e.g., consultant, grantee, etc.). If the author has no such financial relationship, s/he must declare that s/he has nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to provide readers with information on which they can make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.

Chapter 1
Molecular Basis of Hematology
Timothy A. Graubert, James R. Cook and Laura G. Schuettpelz, MD
Dr. Graubert declares no competing financial interests.
Dr. Cook declares no competing financial interests.
Dr. Schuettpelz declares no competing financial interests.

Chapter 2
Consultative Hematology I: Hospital-Based and Selected Outpatient Topics
Donald Arnold, Adam Cuker and Cindy Neunert
Dr Arnold: Consultancy: Amgen; GlaxoSmithKline; Hoffman-LaRoche; Research Funding: Amgen; GlaxoSmithKline; Hoffman LaRoche; Honoraria: Amgen; Membership on board of directors of advisory committee: Amgen; GlaxoSmithKline.
Dr. Cuker: Consultancy: Amgen; GlaxoSmithKline; Research Funding: Baxter; Bayer; Stago.
Dr. Neunert declares no competing financial interests.
Chapter 3
Consultative Hematology II: Women’s Health Issues
Margaret Ragni and Sara O’Brien
Dr. Ragni: Consultancy: Archemix Corporation; Bayer; Biogen Idec; Bristol-Meyers Squibb; Research Funding: Baxter Bioscience; Bayer; Biogen Idec; Bristol-Meyers Squibb; Centers for Disease Control; Children’s Hospital of Philadelphia; CSL Behring; Merck; NHLBI; Novartis; NovoNordisk; Pennsylvania Department of Health; Pfizer; Vascular Medicine Institute: Honoraria: Archemix Corporation; Baxter Bioscience; Bayer: Membership on board of directors of advisory committee: Baxter Healthcare; Foundation for Women and Girls with Blood Disorders; Haemophilia; Hematologist; Journal of Rare Disorders; Journal of Thrombosis and Haemostasis; MCHB HHS Region III Fed HTCs; National Hemophilia Foundation; NHLBI; Vascular Medicine Institute.
Dr. O’Brien: Research Funding: American Diabetes Association; Bayer; GlaxoSmithKline; Hemostasis and Thrombosis Research Society: Membership on board of directors of advisory committee: Apixaban Pediatric Steering Committee; GlaxoSmithKline.

Chapter 4
Hematopoietic Growth Factors
Murat Arcasoy and Gary Lyman
Dr. Arcasoy declares no competing financial interests.
Dr. Lyman: Research Funding: Amgen.

Chapter 5
Iron Metabolism, Iron Overload and the Porphyrias
Marc Kahn, Lawrence Solberg, Jr. and Jecko Thachil
Dr. Kahn declares no competing financial interests.
Dr. Solberg: Membership on board of directors of advisory committee: Community Hospice of Northeast Florida.
Dr. Thachil declares no competing financial interests.

Chapter 6
Acquired Underproduction Anemias
Timothy Littlewood and Siobán Keel
Dr. Littlewood declares no competing financial interests.
Dr. Keel declares no competing financial interests.
Chapter 7
Hemolytic Anemias
Charles Quinn and Charles Packman
Dr. Quinn: Research Funding: Glycomimetics; Lilly.
Dr. Packman declares no competing financial interests.

Chapter 8
Thrombosis and Thrombophilia
Stephan Moll, David Garcia and Anjali Sharathkumar
Dr. Moll: Consultancy: GTC Biotherapeutics; ITC; Talecris.
Dr. Garcia: Consultancy: Bristol-Meyers Squibb; CSL Behring; Daiichi Sankyo;
Research Funding: Bristol-Meyers Squibb.
Dr. Sharathkumar declares no competing financial interests.

Chapter 9
Bleeding Disorders
Jorge Di Paola and Amy Shapiro
Dr. Di Paola: Consultancy: CSL Behring; NovoNordisk.
Dr. Shapiro: Employ: Indiana Hemophilia & Thrombosis Center; Consultancy: Baxter;
Indiana Hemophilia & Thrombosis Center; Novo Nordisk: Research Funding:
Adventrix; Baxter; Bayer Healthcare; Bio Products Laboratory; Biogen IDEC; CSL
Behring; Eli Lilly; Indiana Hemophilia & Thrombosis Center; Inspiration
Biopharmaceuticals; Kedrion Biopharma; Novartis; Novo Nordisk; Octapharma; Pfizer
Pharmaceuticals; Wyeth Pharmaceuticals: Honoraria: Baxter; Biogen IDEC; Indiana
Hemophilia & Thrombosis Center; Inspiration Biopharmaceuticals; Novo Nordisk:
Speakers Bureau: Baxter; Biogen IDEC; Inspiration Biopharmaceuticals; Novo Nordisk:
Membership on board of directors of advisory committee: Baxter; Bayer Healthcare;
Biogen IDEC; Inspiration Biopharmaceuticals; Novo Nordisk.

Chapter 10
Disorders of Platelet Number and Function
A. Koneti Rao and Keith McCrae
Dr. Rao declares no competing financial interests.
Dr. McCrae: Speakers Bureau: Amgen; GlaxoSmithKline: Membership on board of
directors of advisory committee: GlaxoSmithKline.
Chapter 11
Laboratory Hematology
Charles Eby, Jacob Rand and John Frater
Dr. Eby: Consultancy: Bryan Cave Law Firm; Research Funding: Siemens Healthcare Diagnostics: Membership on board of directors of advisory committee: College of American Pathologists; International Society of Laboratory Hematology.
Dr. Rand declares no competing financial interests.
Dr. Frater declares no competing financial interests.

Chapter 12
Transfusion Medicine
Karen Quillen and Suzanne Bakdash
Dr. Quillen declares no competing financial interests.
Dr. Bakdash declares no competing financial interests.

Chapter 13
Cellular Basis of Hematopoiesis and Stem Cell Transplantation
Dan S. Kaufman and David T. Scadden
Dr. Kaufman declares no competing financial interests.
Dr. Scadden: consultancy: Anchor Therapeutics; Bone Therapeutics; Fate Therapeutics; GlaxoSmithKline; Hospira; United Therapeutics: Equity: Fate Therapeutics: Research Funding: GlaxoSmithKline

Chapter 14
Clinical Bone Marrow and Stem Cell Transplantation
Jerald Radich and Sergio Giralt
Dr. Radich: Consultancy: Ariad; Bristol-Meyers Squibb; Novartis; Pfizer: Research Funding: Novartis: Honoraria: Novartis.

Chapter 15
Myeloid Disorders and Congenital Marrow Failure Syndromes
Geoffrey L. Uy and Inderjeet Dokal
Dr. Uy: Consultancy: Genzyme; Novartis; Sanofi-Aventis.
Dr. Dokal: Research Funding: Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts Health; Wellcome Trust: Membership on board of directors of advisory committee: Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts Health; Wellcome Trust, MRC; Gary Woodward Dyskeratosis Congenita Trust; MRC Leukaemia Trials Committee.
Chapter 16
Myeloproliferative Neoplasms
Ross Levine and Ramon V. Tiu
Dr. Levine: Consultancy: TargeGen; Research Funding: Astra Zeneca; Novartis.
Dr. Tiu: Honoraria: Cleveland Clinic (attending advisory meetings for Alexion; Incyte; Allos Therapeutics).

Chapter 17
Acquired Marrow Failure Syndromes: Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, and Myelodysplastic Syndromes
Phillip Scheinberg and David P. Steensma
Dr. Scheinberg declares no competing financial interests.
Dr. Steensma: Consultancy: Celgene; Novartis: Research Funding: Amgen:
Honoraria: Johnson & Johnson; Membership on board of directors of advisory committee: American Society of Clinical Oncology; Amgen; Amgen; Aplastic Anemia and MDS International Foundation; Johnson & Johnson; Myelodysplastic Syndromes Foundation

Chapter 18
Acute Myeloid Leukemia
Lillian Sung and B. Douglas Smith
Dr. Sung declares no competing financial interests.
Dr. Smith declares no competing financial interests.

Chapter 19
Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Daniel J. DeAngelo and Ching-Hon Pui
Dr. DeAngelo: Consultancy: Bristol-Meyers Squibb; Novartis: Research Funding: Bristol-Meyers Squibb.
Dr. Pui: Honoraria: EUSA Pharma; Sanofi-Aventis.

Chapter 20
Hodgkin Lymphoma
Kristie A. Blum and Ann LaCasce
Dr. Blum: Research Funding: Celgene; Immunomedics; Millennium; Novartis; Pharmacyclics; Seattle Genetics.
Dr. LaCasce declares no competing financial interests.
Chapter 21
Non-Hodgkin Lymphoma
Kerry Joanne Savage and Brad S. Kahl
Dr. Savage: Consultancy: Allos Therapeutics, Inc.; Celgene; Seattle Genetics;
Research Funding: Roche; Honoraria: Allos Therapeutics, Inc.; Seattle Genetics;
Membership on board of directors of advisory committee: Allos Therapeutics, Inc.
Dr. Kahl: Research Funding: Genentech; Millennium; Membership on board of
directors of advisory committee: Celgene; Millennium; Seattle Genetics

Chapter 22
Chronic Lymphocytic Leukemia
Grzegorz S. Nowakowski and Vicki A. Morrison
Dr. Nowakowski declares no competing financial interests.
Dr. Morrison: Speakers Bureau: Amgen; Genentech; Membership on board of
directors of advisory committee: Celgene; Merck.

Chapter 23
Plasma Cell Disorders
Irene Ghobrial and Martha Lacy
Dr. Ghobrial: Consultancy: Celgene; Research Funding: Millennium; Novartis;
Honoraria: Celgene; Millennium; Novartis; Speakers Bureau: Celgene; Novartis;
Membership on board of directors of advisory committee: Celgene; Millennium.
Dr. Lacy: Research Funding: Celgene.

In compliance with ACCME policy, the American Society of Hematology also requires all authors to disclose any discussion of off-label drug use.

Consultative Hematology I: Hospital-Based and Selected Outpatient Topics
Dr. Arnold will discuss cyclophosphamide and rituximab for use in antiphospholipid antibody syndrome.
Dr. Cuker will discuss desmopressin for use in platelet function disorders; Desmopressin, Recombinant FVIIa, Prothrombin complex concentrate, Activated prothrombin complex concentrate, and Tranexamic acid for use in surgical bleeding; Conjugated estrogens for use in uremic bleeding; Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for use in post-renal transplant erythrocytosis; Rituximab for use in CD20+ post-transplant lymphoproliferative disorder.
Dr. Neunert will discuss rituximab, thrombopoietin (TPO) receptor agonists, and high-dose dexamethasone for use in pediatric ITP; Corticosteroids and vincristine for use in Kasabach-Merritt syndrome (KMS).

**Hematopoietic Growth Factors**

Dr. Arcasoy will discuss epoetin alfa and darbepoetin alfa in myelodysplastic syndromes.

**Iron Metabolism, Iron Overload and the Porphyrias**

Dr. Solberg will discuss beta-carotene for erythropoietic protoporphyria and chloroquine for porphyria cutanea tarda.

**Hemolytic Anemias**

Dr. Packman will discuss rituximab, cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine and danazol in the treatment of autoimmune hemolytic anemia.

**Bleeding Disorders**

Dr. Di Paola will discuss rFVIIa for management of bleeding in hemophilia at doses and regimens that are not approved and for other off-label indications; prothrombin complex concentrates for treatment of warfarin overdose, vitamin K deficiency, and liver disease.

Dr. Shapiro will discuss rFVIIa for high-dose therapy and rare disorders.

**Disorders of Platelet Number and Function**

Dr. Rao will discuss desmopressin for management of patients with inherited platelet function defects and renal failure. Recombinant VIIa for management of patients with inherited platelet function defects.

Dr. McCrae will discuss rituximab for ITP and TTP.
Transfusion Medicine

Dr. Quillen will discuss recombinant activated Factor VII for refractory bleeding.

Dr. Bakdash will discuss recombinant activated Factor VII for refractory bleeding.

Clinical Bone Marrow and Stem Cell Transplantation

Dr. Giralt will discuss drug therapy for stem cell transplantation.

Myeloproliferative Neoplasms

Dr. Tiu will discuss thalidomide in anemia in myelofibrosis; cladribine in treatment of hepatomegaly post-spelenectomy in myelofibrosis; interferon-alpha as cytoreductive therapy for polycythemia vera and essential thrombocytopenia and pregnancy in essential thrombocytopenia.

Acquired Marrow Failure Syndromes: Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, and Myelodysplastic Syndromes

Dr. Scheinberg will discuss alemtuzumab, eltrombopag and high-dose cyclophosphamide in aplastic anemia; androgenic steroids in paroxysmal nocturnal hemoglobinuria.

Dr. Steensma will discuss alemtuzumab, eltrombopag and high-dose cyclophosphamide in aplastic anemia; androgenic steroids in paroxysmal nocturnal hemoglobinuria.

Hodgkin Disease

Dr. Blum will discuss rituximab for the treatment of lymphocyte predominant Hodgkins.

Dr. LaCasce will discuss rituximab for the treatment of lymphocyte predominant Hodgkins.

Non-Hodgkin Lymphoma
Dr. Savage will discuss rituximab for follicular lymphoma and management of PTLD. Fludarabine and mitoxantrone as primary therapy for indolent lymphomas; bendamustine as primary therapy for indolent lymphomas and mantle cell lymphoma; etoposide in DLBCL, PMBCL and BL (DA-EPOCHR). GA-101 in DLBCL; brentuximab vedotin in cutaneous ALCL; and alemtuzumab, gemcitabine and rituximab for PTCLs. L-asparaginase in NK/TCLs.

Dr. Kahl will discuss rituximab for follicular lymphoma and management of PTLD. Fludarabine and mitoxantrone as primary therapy for indolent lymphomas; bendamustine as primary therapy for indolent lymphomas and mantle cell lymphoma; etoposide in DLBCL, PMBCL and BL (DA-EPOCHR). GA-101 in DLBCL; brentuximab vedotin in cutaneous ALCL; and alemtuzumab, gemcitabine and rituximab for PTCLs. L-asparaginase in NK/TCLs.

**Chronic Lymphocytic Leukemia**

Dr. Nowakowski will discuss lenalidomide, ibrutinib, everolimus, flavopiridol and GS1101.